LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Anselamimab Shows Promise In AL Amyloidosis Despite Missing Main Endpoint
AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical significance for its primary endpoint in AL amyloidosis, although it showed promise in a specific subgroup. Over the last quarter, AstraZeneca's price moved 3%, in line with the market's trend as major indexes hit record highs. Positive developments like the successful Baxdrostat trial, Imfinzi approval in the EU, and strong earnings performance likely added weight to broader...